|8. Switch to an IL-17i biologic over adding MTX to an IL-12/23i biologic (PICO 37).|Very low|
|Conditional recommendation based on very-low-quality evidence; may consider adding MTX in patients with only partial response to the current therapy or in those who potentially have not had enough time to adequately respond.| |</p>